Zimmer Biomet Holdings (ZBH) Receives a Hold from Bank of America Securities

Bank of America Securities analyst Travis Steed reiterated a Hold rating on Zimmer Biomet Holdings today and set a price target of $100.00.

Introducing TipRanks MCP for Agents

• Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
• Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.

Steed covers the Healthcare sector, focusing on stocks such as Boston Scientific, Intuitive Surgical, and Stryker. According to TipRanks, Steed has an average return of 0.8% and a 49.27% success rate on recommended stocks.

In a report released on June 1, Wells Fargo also assigned a Hold rating to the stock with a $90.00 price target.

Based on Zimmer Biomet Holdings’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $2.09 billion and a net profit of $238.1 million. In comparison, last year the company earned a revenue of $1.91 billion and had a net profit of $182 million

Based on the recent corporate insider activity of 34 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZBH in relation to earlier this year. Earlier this month, Sang Yi, the Group President, Asia Pacific of ZBH sold 5,000.00 shares for a total of $413,216.00.